Logo image of URGN

UROGEN PHARMA LTD (URGN) Stock Fundamental Analysis

NASDAQ:URGN - Nasdaq - IL0011407140 - Common Stock - Currency: USD

10.08  -0.63 (-5.88%)

After market: 10.2677 +0.19 (+1.86%)

Fundamental Rating

3

URGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. URGN has a bad profitability rating. Also its financial health evaluation is rather negative. URGN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

URGN had negative earnings in the past year.
In the past year URGN has reported a negative cash flow from operations.
In the past 5 years URGN always reported negative net income.
In the past 5 years URGN always reported negative operating cash flow.
URGN Yearly Net Income VS EBIT VS OCF VS FCFURGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -38.21%, URGN perfoms like the industry average, outperforming 58.08% of the companies in the same industry.
URGN's Return On Equity of -452.20% is on the low side compared to the rest of the industry. URGN is outperformed by 79.57% of its industry peers.
Industry RankSector Rank
ROA -38.21%
ROE -452.2%
ROIC N/A
ROA(3y)-76.96%
ROA(5y)-77.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
URGN Yearly ROA, ROE, ROICURGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

URGN has a Gross Margin of 90.27%. This is amongst the best in the industry. URGN outperforms 93.43% of its industry peers.
URGN's Gross Margin has been stable in the last couple of years.
URGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.02%
GM growth 5YN/A
URGN Yearly Profit, Operating, Gross MarginsURGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100K -200K -300K -400K -500K

More info and screens

3

2. Health

2.1 Basic Checks

URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, URGN has more shares outstanding
Compared to 5 years ago, URGN has more shares outstanding
The debt/assets ratio for URGN has been reduced compared to a year ago.
URGN Yearly Shares OutstandingURGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
URGN Yearly Total Debt VS Total AssetsURGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

URGN has an Altman-Z score of -2.16. This is a bad value and indicates that URGN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.16, URGN perfoms like the industry average, outperforming 51.87% of the companies in the same industry.
A Debt/Equity ratio of 4.77 is on the high side and indicates that URGN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 4.77, URGN is doing worse than 84.37% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.77
Debt/FCF N/A
Altman-Z -2.16
ROIC/WACCN/A
WACC8.67%
URGN Yearly LT Debt VS Equity VS FCFURGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 9.00 indicates that URGN has no problem at all paying its short term obligations.
The Current ratio of URGN (9.00) is better than 76.38% of its industry peers.
A Quick Ratio of 8.77 indicates that URGN has no problem at all paying its short term obligations.
URGN's Quick ratio of 8.77 is fine compared to the rest of the industry. URGN outperforms 75.13% of its industry peers.
Industry RankSector Rank
Current Ratio 9
Quick Ratio 8.77
URGN Yearly Current Assets VS Current LiabilitesURGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.53% over the past year.
The Revenue has grown by 15.65% in the past year. This is quite good.
The Revenue has been growing by 135.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.12%
Revenue 1Y (TTM)15.65%
Revenue growth 3Y91.38%
Revenue growth 5Y135.99%
Sales Q2Q%20.87%

3.2 Future

URGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.89% yearly.
Based on estimates for the next years, URGN will show a very strong growth in Revenue. The Revenue will grow by 47.97% on average per year.
EPS Next Y13.77%
EPS Next 2Y11.04%
EPS Next 3Y23.5%
EPS Next 5Y24.89%
Revenue Next Year11.26%
Revenue Next 2Y26.67%
Revenue Next 3Y49.85%
Revenue Next 5Y47.97%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
URGN Yearly Revenue VS EstimatesURGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
URGN Yearly EPS VS EstimatesURGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for URGN. In the last year negative earnings were reported.
Also next year URGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
URGN Price Earnings VS Forward Price EarningsURGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
URGN Per share dataURGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

URGN's earnings are expected to grow with 23.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.04%
EPS Next 3Y23.5%

More info and screens

0

5. Dividend

5.1 Amount

URGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UROGEN PHARMA LTD

NASDAQ:URGN (2/21/2025, 8:00:01 PM)

After market: 10.2677 +0.19 (+1.86%)

10.08

-0.63 (-5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners94.03%
Inst Owner Change3.26%
Ins Owners2.24%
Ins Owner Change0.7%
Market Cap425.38M
Analysts83.33
Price Target38.42 (281.15%)
Short Float %16.29%
Short Ratio16.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.39%
Min EPS beat(2)-7.23%
Max EPS beat(2)34.01%
EPS beat(4)1
Avg EPS beat(4)3.29%
Min EPS beat(4)-9.81%
Max EPS beat(4)34.01%
EPS beat(8)4
Avg EPS beat(8)4.78%
EPS beat(12)7
Avg EPS beat(12)4.46%
EPS beat(16)9
Avg EPS beat(16)3.87%
Revenue beat(2)1
Avg Revenue beat(2)-4.26%
Min Revenue beat(2)-10.61%
Max Revenue beat(2)2.09%
Revenue beat(4)2
Avg Revenue beat(4)-5.05%
Min Revenue beat(4)-13.88%
Max Revenue beat(4)2.22%
Revenue beat(8)4
Avg Revenue beat(8)-2.65%
Revenue beat(12)4
Avg Revenue beat(12)-5.39%
Revenue beat(16)6
Avg Revenue beat(16)-6.2%
PT rev (1m)0%
PT rev (3m)-2.02%
EPS NQ rev (1m)-4.14%
EPS NQ rev (3m)0.6%
EPS NY rev (1m)-2.24%
EPS NY rev (3m)3.65%
Revenue NQ rev (1m)-1.76%
Revenue NQ rev (3m)-5.33%
Revenue NY rev (1m)-1.08%
Revenue NY rev (3m)-1.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.76
P/FCF N/A
P/OCF N/A
P/B 16.67
P/tB 16.67
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-2.86
Fwd EYN/A
FCF(TTM)-2.28
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS2.12
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.21%
ROE -452.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.27%
FCFM N/A
ROA(3y)-76.96%
ROA(5y)-77.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.02%
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 4.77
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.66%
Cap/Sales 0.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9
Quick Ratio 8.77
Altman-Z -2.16
F-Score5
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)47.24%
Cap/Depr(5y)108.44%
Cap/Sales(3y)0.73%
Cap/Sales(5y)332.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.12%
EPS Next Y13.77%
EPS Next 2Y11.04%
EPS Next 3Y23.5%
EPS Next 5Y24.89%
Revenue 1Y (TTM)15.65%
Revenue growth 3Y91.38%
Revenue growth 5Y135.99%
Sales Q2Q%20.87%
Revenue Next Year11.26%
Revenue Next 2Y26.67%
Revenue Next 3Y49.85%
Revenue Next 5Y47.97%
EBIT growth 1Y-17.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.92%
EBIT Next 3Y14.54%
EBIT Next 5YN/A
FCF growth 1Y-11.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.95%
OCF growth 3YN/A
OCF growth 5YN/A